| David Jacobs |
David Jacobs currently works at Beacon Therapeutics (USA), Inc., as Senior VP-Clinical Research & Medical Affairs from 2022. |
| Susan Schneider |
Currently, Susan Schneider is Chief Medical Officer of Applied Genetic Technologies Corp.
In the past she was Chief Medical Officer for Oxurion NV, Senior Vice President-Clinical Development at Jixing Pharmaceutical Technology (Shanghai) Co. Ltd., Director-Clinical & Scientific Affairs at Bausch & Lomb, Inc., Medical Director for Genentech, Inc., Chief Medical Officer at Santen, Inc., Senior Director-Ophthalmology at GlaxoSmithKline LLC, Principal at New York Eye & Ear Infirmary and Principal at The University of Cincinnati College of Medicine.
She received an undergraduate degree from the University of Pennsylvania. |
| Abraham Scaria |
Abraham Scaria is currently the Chief Scientific Officer at Beacon Therapeutics (USA), Inc. He previously worked as the Senior Scientific Director-Gene Therapy at Genzyme Corp., Chief Scientific Officer at IVERIC bio, Inc., Head-Gene Therapy Research at Sanofi Corp., and Vice President & Head-Ophthalmology at Casebia Therapeutics LLC. Scaria received a graduate degree from the University of Mumbai and a doctorate degree from The Indiana University School of Medicine. |
| Nadia Waheed |
Nadia Waheed is currently the Chief Medical Officer at Beacon Therapeutics (USA), Inc. and Gyroscope Therapeutics Holdings Plc. Prior to her current positions, she worked as the Director at Boston Image Reading Center LLC from 2015 to 2020. She holds a graduate degree from Harvard T.H. Chan School of Public Health and a doctorate degree from Aga Khan University. |
| Gerald A. Reynolds |
Gerald A. Reynolds has a current job as the Treasurer at Beacon Therapeutics (USA), Inc. |
| Sarah C. DiSalvatore |
Sarah C. DiSalvatore holds the position of Vice President-Clinical Operations at Applied Genetic Technologies Corp.
In the past she held the position of Associate Vice President-Clinical Operations at Rocket Pharmaceuticals, Inc. |
| Matthew Feinsod |
Matthew Feinsod was the founder of Imagen Biotech, Inc. (founded in 2011) and held the title of Chief Medical Officer. He is currently the Director at World Eye Mission and the Executive VP-Global Strategy & Development at Beacon Therapeutics (USA), Inc. (since 2019). Dr. Feinsod's former positions include Senior VP-Strategy & Product Development at Oldtech, Inc., Member-Institutional Review Board at The George Washington University Hospital, and Medical Officer at the US Food & Drug Administration. He holds a doctorate degree from George Washington University and an undergraduate degree from The Wharton School of the University of Pennsylvania. |
| David A. Fellows |
David A. Fellows is currently the Chief Executive Officer & Secretary at Beacon Therapeutics (USA), Inc. He is also the Chairman at Oxular Ltd. and Terns Pharmaceuticals, Inc. Additionally, he serves as the Director at Glaucoma Foundation and Gyroscope Therapeutics Ltd. Furthermore, he holds positions as a Director at Jaguar Therapeutics, Arctos Medical, and Jaguar Gene Therapy LLC. In his former roles, Mr. Fellows served as the Chief Executive Officer & Director at Nightstar Therapeutics Ltd. from 2017 to 2019. He was also the Managing Director at Allergan Ltd. and a Director at NightstaRx Ltd. and Axovia Therapeutics, Inc. Moreover, he held the position of Non-Executive Director at Gyroscope Therapeutics Holdings Plc from 2020 to 2022. Additionally, he worked as a Vice President at Allergan, Inc. and Johnson & Johnson Vision Care, Inc. from 2005 to 2014. Mr. Fellows completed his undergraduate degree at Butler University. |
| Stephen W. Potter |
Stephen W. Potter currently works at Beacon Therapeutics (USA), Inc., as Chief Business Officer & Vice President from 2015. Mr. Potter also formerly worked at Osiris Therapeutics, Inc., as SVP-Operations & Corporate Development from 2011 to 2012, Genzyme Corp., as Senior VP-Corporate & Business Development from 2006 to 2010, NeoStem, Inc., as Executive Vice President from 2013 to 2015, and Caladrius Biosciences, Inc., as Executive Vice President from 2013 to 2015. Mr. Potter received his undergraduate degree in 1979 from the University of Massachusetts and Masters Business Admin degree from Harvard Business School. |
| Scott E. Koenig |
Founder of MacroGenics, Inc., Scott E. Koenig currently holds the position of Chairman at Applied Genetic Technologies Corp. and President, Chief Executive Officer & Director at MacroGenics, Inc. Dr. Koenig is also on the board of Biotechnology Innovation Organization, GlycoMimetics, Inc. and The International Biomedical Research Alliance and Member of Cornell University Council.
Dr. Koenig previously held the position of Senior Vice President-Research at Medimmune, Inc., Principal at National Institute of Allergy & Infectious Diseases, Chairman of Children's Research Institute, Inc., Principal at National Institutes of Health and Trustee-Advisory Board at Cornell University.
He received a doctorate and an undergraduate degree from Cornell University and a doctorate from The University of Texas Health Science Center at Houston. |
| Jonathan I. Lieber |
Presently, Jonathan I. Lieber is Chief Financial Officer of Applied Genetic Technologies Corp. Mr. Lieber is also on the board of Salarius Pharmaceuticals, Inc. and Member-Audit Committee at Atrius Health, Inc.
In the past Mr. Lieber held the position of Chief Financial Officer at Danforth Advisors LLC, President & Chief Financial Officer of Organovo Holdings, Inc., Chief Financial Officer & Treasurer for Repligen Corp., Chief Financial Officer & Senior Vice President for Metamark Genetics, Inc., Chief Financial Officer, Treasurer & Senior VP of Altus Pharmaceuticals, Inc., Chief Financial Officer & Treasurer for Xcellerex, Inc., Chief Financial Officer of Histogenics Corp., Chief Financial Officer for Checkmate Pharmaceuticals, Inc., Vice President at Cowen & Co. LLC and Member-Health Care & High Yield Group at Salomon Brothers, Inc.
Jonathan I. Lieber received an undergraduate degree from Boston University and an MBA from The Leonard N Stern School of Business. |
| Susan B. Washer |
Currently, Susan B. Washer is President, Chief Executive Officer & Director at Applied Genetic Technologies Corp. Ms. Washer is also on the board of 7 other companies.
In her past career she held the position of President & Chief Executive Officer of Scenic Productions, Inc., Principal at Eli Lilly & Co. and Principal at Abbott Laboratories (Pakistan) Ltd.
Ms. Washer received an undergraduate degree from Michigan State University, an MBA from Warrington College of Business Administration and an MBA from the University of Florida. |
| Anne M. VanLent |
Founder of Technology Compass Group LLC and AMV Advisors, Anne M. VanLent currently occupies the position of President of AMV Advisors. She is also on the board of 6 other companies.
In her past career Ms. VanLent occupied the position of Chief Financial Officer for Neurogenics, Inc., Principal at Technology Compass Group LLC, Chief Financial Officer & Senior Vice President at The Liposome Co., Inc., Chief Financial Officer & Executive Vice President of Barrier Therapeutics, Inc. and Executive Vice President-Portfolio Management at Sarnoff Corp.
She received an undergraduate degree from Mount Holyoke College. |
| Edward M. Hurwitz |
Edward M. Hurwitz founded Precision BioVentures LLC and Viewpoint Therapeutics, Inc. Presently, Mr. Hurwitz is Chairman at Rekindle Therapeutics, Inc., Chairman at Biointervene, Inc., Chief Financial Officer for Turmeric Acquisition Corp., Managing Director at Precision BioVentures LLC, Managing Director at MPM Capital Inc and Chairman of Viewpoint Therapeutics, Inc. Mr. Hurwitz is also Manager for Alta Embarcadero Biopharma Partners III LLC and on the board of 6 other companies.
In the past he held the position of Director at Alta Partners Management Corp. and Chief Financial Officer & Senior Vice President of Affymetrix, Inc.
He received an undergraduate degree from Cornell University, an MBA from Haas School of Business and a graduate degree from Berkeley Law University of California. |
| Ivana Magovcevic-Liebisch |
Currently, Ivana Magovcevic-Liebisch holds the position of Chairman of Absci Corp. and President, Chief Executive Officer & Director at Vigil Neuroscience, Inc. She is also on the board of 5 other companies.
She previously held the position of Senior VP & Head-Global Business Development at Teva Pharmaceutical Industries Ltd., Chief Business Officer & Executive Vice President at Ipsen SA, Executive VP, Chief Strategy & Development Officer at Axcella Health, Inc., Chief Operating Officer & Executive Vice President for Dyax Corp. and Director-Intellectual Property & Patent Counsel at Transkaryotic Therapies, Inc.
Dr. Magovcevic-Liebisch received a doctorate from Harvard University, a graduate degree from Suffolk University Law School and an undergraduate degree from Wheaton College (Illinois). |
| James Rosen |
James Rosen is on the board of Applied Genetic Technologies Corp. and Director-Public Health Foundation at Unc Gillings School of Global Public Health.
Mr. Rosen previously occupied the position of President & Chief Executive Officer at Artizan Biosciences, Inc., Partner at Intersouth Partners and Partner at Intersouth Associates VI LLC (a subsidiary of Intersouth Partners), Equity Research Analyst at Brean Murray & Co., Principal at The Robert Wood Johnson Foundation, Deputy Director-Venture Investing at Bill & Melinda Gates Foundation Trust and Principal at Duke University Medical Center.
Mr. Rosen received an undergraduate degree from Duke University, a graduate degree from Unc Gillings School of Global Public Health and an MBA from Kenan-Flagler Business School. |
| Arnold Lewis Oronsky |
Arnold Lewis Oronsky is currently the Chairman at EpicentRx, Inc. He also holds director positions at Kanisa Pharmaceuticals, Inc., Arcion Therapeutics LLC, Drais Pharmaceuticals Inc., Tesaro, Inc., Centrexion Therapeutics Corp., Potenza Therapeutics, Inc., Integrated Diagnostics, Inc., KalVista Pharmaceuticals Ltd., and Prothex Pharmaceuticals, Inc. In his former roles, Dr. Oronsky served as the Chairman at Dynavax Technologies Corp. from 2006 to 2020. He was also a director at BioTransplant, Inc., Corixa Corp., Anesiva, Inc., Gilead Colorado, Inc., Metabasis Therapeutics, Inc., Aspreva Pharmaceuticals Corp., Diatos SA, AkaRx, Inc., Amplimmune, Inc., USDS, Inc., MacroGenics, Inc., AlgoRx Pharmaceuticals, Inc., InterWest Partners LLC, Beacon Therapeutics (USA), Inc., Sera Prognostics, Inc., PMV Pharmaceuticals, Inc., Tizona Therapeutics, Inc., KalVista Pharmaceuticals, Inc., Wyeth Holdings LLC, Ciba-Geigy Corp., Lederle Laboratories, and Ciba-Geigy Pharmaceuticals. Dr. Oronsky completed his undergraduate studies at New York University and obtained a doctorate degree from Columbia University College of Physicians & Surgeons. |
